Colorectal Adenocarcinoma

About
Mappings

OncoTree: Colorectal Adenocarcinoma (oncotree:COADREAD)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
FDA (1) HC (1) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Irinotecan
FDA (1) HC (1) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Irinotecan
FDA (1) HC (2) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab
FDA (2) HC (1) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib
FDA (2) MSI-H Colorectal Adenocarcinoma Ipilimumab, Nivolumab
FDA (1) Wild type HRAS, Wild type KRAS Colorectal Adenocarcinoma Fluorouracil, Oxaliplatin, Panitumumab
FDA (1) Wild type HRAS, Wild type KRAS Colorectal Adenocarcinoma Panitumumab
FDA (1) HC (1) dMMR Colorectal Adenocarcinoma Pembrolizumab
FDA (1) HC (1) MSI-H Colorectal Adenocarcinoma Pembrolizumab
FDA (1) KRAS p.G12C Colorectal Adenocarcinoma Adagrasib, Cetuximab
FDA (2) dMMR Colorectal Adenocarcinoma Ipilimumab, Nivolumab
FDA (1) MSI-H Colorectal Adenocarcinoma Nivolumab
FDA (1) dMMR Colorectal Adenocarcinoma Nivolumab
FDA (1) HC (1) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin
HC (1) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Panitumumab
FDA (1) HER2-positive, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Trastuzumab, Tucatinib
FDA (1) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib, Fluorouracil, Irinotecan